Characterizing Pharmacogenomic‐Guided Medication Use With a Clinical Data Repository

The extent to which pharmacogenomic‐guided medication use has been adopted in various health systems is unclear. To assess the uptake of pharmacogenomic‐guided medication use, we determined its frequency across our health system, which does not have a structured testing program. Using a multisite cl...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2017-08, Vol.102 (2), p.340-348
Main Authors: Mathias, PC, Hendrix, N, Wang, W‐J, Keyloun, K, Khelifi, M, Tarczy‐Hornoch, P, Devine, B
Format: Article
Language:English
Subjects:
Adult
Aged
Cohort Studies
Databases, Factual - trends
Drug Utilization - trends
Female
Humans
Male
Middle Aged
Pharmacogenetics - methods
Pharmacogenetics - trends
Pharmacogenomic Testing - methods
Pharmacogenomic Testing - trends
Precision Medicine - methods
Precision Medicine - trends
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The extent to which pharmacogenomic‐guided medication use has been adopted in various health systems is unclear. To assess the uptake of pharmacogenomic‐guided medication use, we determined its frequency across our health system, which does not have a structured testing program. Using a multisite clinical data repository, we identified adult patients' first prescribed medications between January 2011 and December 2013 and investigated the frequency of germline and somatic pharmacogenomic testing, by the Pharmacogenomics Knowledgebase level of the US Food and Drug Administration label information. There were 268,262 medication orders for drugs with germline pharmacogenomic testing information in their drug labels. Pharmacogenomic testing was detected for 1.5% (129/8,718) of medication orders with recommended or required testing. Of the 3,817 medication orders associated with somatic pharmacogenomic testing information in their drug labels, 20% (372/1,819) of required tests were detected. The low rates of detectable pharmacogenomic testing suggest that structured testing programs are required to achieve the success of precision medicine.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.611